{"id":"W3004601288","doi":"10.1053/j.gastro.2020.01.047","title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease","year":2020,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":317,"is_retracted":false,"has_abstract":true,"ca_institutions":"St Joseph's Health Care; Robarts Clinical Trials; Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Genentech; National Institutes of Health; Dr. Falk Pharma; Tillotts Pharma; Vifor Pharma; Shire; Roche España; AstraZeneca España; Janssen Research and Development; UCB; Bristol-Myers Squibb; Nestlé Health Science; Johnson and Johnson; Teva Pharmaceutical Industries; Meso Scale Diagnostics; Takeda Pharmaceutical Company; Atlantic Healthcare; ActoGeniX; Amgen; Boehringer Ingelheim; Schering-Plough; AbbVie; Ipsen Biopharmaceuticals; Elan; Celgene; Pfizer; Biogen; Merck; Allergan; Seres Therapeutics; AstraZeneca; Boehringer Ingelheim España; Eli Lilly and Company; Janssen Pharmaceuticals; Johns Hopkins University; Crohn's and Colitis Foundation of America; Gilead Sciences; Arrien Pharmaceuticals; California Community Foundation","keywords":"Medicine; Crohn's disease; Randomized controlled trial; Crohn disease; Internal medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001328294,0.0001113002,0.0003636645,0.00003312834,0.000009480709,0.000001943721,0.00008897019,0.00004511563,0.00001710759],"category_scores_gemma":[0.0002639974,0.00009241032,0.00007433918,0.00002699397,0.0002586501,0.000002679946,0.00007763448,0.000048053,5.194576e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003135235,"about_ca_system_score_gemma":0.00003858242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002248394,"about_ca_topic_score_gemma":0.00001033704,"domain_scores_codex":[0.9989249,0.0002511116,0.0003596808,0.0002211648,0.00008437606,0.0001587624],"domain_scores_gemma":[0.9994749,0.00002083098,0.0001709206,0.000152205,0.00005287791,0.0001283012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7989097,0.0001699448,0.2003278,0.0000378443,0.00005458149,0.00001846199,0.00004335999,0.00004020864,0.0003068323,0.00001179984,0.00002147778,0.0000580587],"study_design_scores_gemma":[0.5065889,0.0006057322,0.4926265,0.000007841011,0.00003484197,1.956702e-7,0.000004347439,0.00002237668,0.00004835604,0.000003749295,0.00002492754,0.0000321289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985635,0.00001733616,0.0002674912,0.0001295979,0.0000289023,0.0008724377,0.00009075544,0.00000311549,0.00002682041],"genre_scores_gemma":[0.9993919,0.00001450233,0.0001345497,0.0002716684,0.00003481748,0.00003388671,0.000104638,0.00001060463,0.000003476245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2923207,"threshold_uncertainty_score":0.3768384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004686295959604195,"score_gpt":0.2075357803414565,"score_spread":0.2028494843818523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}